Business Context and Reporting Period
This Form 8-K, dated February 16, 2018, reports on Dandrit Biotech USA, Inc. ("DanDrit"). The filing details the completion of the acquisition of Enochian Biopharma, Inc. ("Enochian"), making Enochian a wholly-owned subsidiary. As a result, DanDrit obtained an exclusive, royalty-free license to combinatory gene therapy platforms for HIV and AIDS treatment. The company also submitted an application to list its common stock on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Enochian stockholders received 18,081,962 shares of DanDrit common stock, representing 50% of the post-acquisition outstanding stock. Additionally, DanDrit forgave $460,690.53 in indebtedness under a promissory note.
- Capital Raise: Simultaneously with the closing, DanDrit completed private placements selling 1,677,130 shares of common stock at $8.00 per share, generating aggregate proceeds of $13,417,040.
- Financial Statements: The filing states that financial statements of the acquired business and pro forma financial information are not included in this report and will be filed by amendment.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the reporting period.
Material Changes
The primary material change is the structural transformation of the company through the merger with Enochian. This transaction doubled the equity base for Enochian stockholders (50% ownership) and significantly altered the company's asset portfolio by adding exclusive intellectual property rights in the HIV/AIDS field. The company also moved from its previous trading status to a pending listing on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Listing Status: DanDrit submitted its initial listing application to the Nasdaq Capital Market on February 20, 2018. Management notes there can be no assurance that Nasdaq will approve the listing.
- Future Filings: Required financial statements and pro forma information regarding the merger are pending and will be submitted via amendment to this report.
- Contingencies: The private placement and merger were contingent upon the satisfaction of conditions outlined in the Merger Agreement dated January 12, 2018.
Investor Verification Checklist
- Verify the approval status of the Nasdaq Capital Market listing application.
- Review the upcoming amendment to this 8-K for the financial statements of Enochian and pro forma financial information.
- Confirm the final share count and ownership structure following the issuance of 18,081,962 shares to Enochian stockholders and the private placement shares.
- Examine the terms of the exclusive license agreement for the HIV/AIDS technology platform (Exhibit 10.1).